Daniel Barenboim, Parkinson's disease
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
11hon MSN
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Sharon Osbourne has opened up about the declining health of her husband Ozzy Osbourne amid his ongoing battle with ...
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results